0'				
Substitute Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866	
	closure Statement pplicant	Applicant Stern et al.,		
(Use several si	heets if necessary)	Filing Date April 14, 2004	Group Art Unit 1632	

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/UJ/	A1	US 2003/0044389 A1	03/06/2003	Brown et al.	424	93.7	
	A2						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	B1							
	B2							

Examin Initial		sig. D		Document	
/UJ/ C1		Cl	(1996)	antigen-specific T lymphocytes," Science 274(5284):94-96	
		C2	Baum and Staines, "MHC-derived pep autoimmune disease," Cytokines Cell M	ortides and the CD4+ T-cell repertoire: Implications for Mol. Ther. 3(2):115-126 (1997)	
		C3	26(1):368-371 (1998)	MHC-binding peptides: update 1997,"Nucleic Acids Res.	
		C4	Cameron et al., "Labeling antigen-spec Immunol. Methods 268(1):51-69 (2002)	cific CD4(+) T cells with class II MHC oligomers,"J.	
		C5	Cantrell, "T-cell antigen receptor signa	al transduction,"Immunology 105(4):369-374 (2002)	
	(C6	Carvalho et al., "ELISPOT assay to me Immunol. Methods 252(1-2):207-218 (easure antigen-specific murine CD8(+) T cell responses,"J. (2001)	
	(C7		rocessed peptides bound to HLA-DR1 are derived from MHC us in size," Nature 358(6389):764-768 (1992).	
		C8	Constantin et al., "Major Histocompatievaluation," Biol. Res. Nurs. 4(2):115-1	ibility Complex (MHC) tetramer technology: an 127 (2002)	
	(C9		me-linked immunospot (ELISPOT) assay for enumeration of amunol. Methods 65(1-2):109-121 (1983)	
	C	210		assay for clonal analysis of cytokine production. I. reting cells," J. Immunol. Methods 110:29-36 (1988)	
	C	C11	Davis et al., "Ligand recognition by al (1998)	pha beta T cell receptors,"Annu. Rev. Immunol. 16:523-544	
	C	C12	ElGhazali et al., "Number of interleukin-4- and interferon-γ-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation," Eur. J. Immunol. 23:2740-2745 (1993)		
	Ewen and Baca-Estrada, "Evaluation of interleukin-4 concentration by ELISA is influenced to consumption of IL-4 by cultured cells," J. Interferon Cytokine Res. 21:39-43 (2001)				
\overline{V}	C	C14	Gabrielsson et al., "Specific induction	of interleukin-4-producing cells in response to in vitro als,"Clin. Exp. Allergy 27:808-815 (1997)	
Examiner	Signature		/Unsu Jung/	Date Considered 03/27/2007	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866	
	closure Statement pplicant	Applicant Stern et al.,		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 14, 2004	Group Art Unit 1632	

(Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
/UJ/	C15	Germain, "MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation," Cell 76(2):287-299 (1994)
	C16	Geysen et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," Proc. Natl. Acad. Sci. USA 81(13):3998-4002 (1984)
	C17	Gorga et al., "Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line," J. Biol. Chem. 262(33):16087-16094 (1995) 1987
	C18	Grey et al., "Class I MHC-peptide interactions: structural requirements and functional implications," Cancer Surv. 22:37-49 (1995)
	C19	Hammer et al., "HLA class II peptide binding specificity and autoimmunity," Adv. Immunol. 66:67-100 (1997)
	C20	Hartemann et al., "Abscence of significant Th2 response in diabetes-prone non-obese diabetic (NOD) mice," Clin. Exp. Immunol. 116:225-230 (1999)
	C21	Hennecke and Wiley, "T cell receptor-MHC interactions up close," Cell 104(1):1-4 (2001)
	C22	Huang et al., "Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG),"Clin. Exp. Immunol. 118:304-308 (1999)
	C23	Hunt et al., "Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry," Science 255(5049):1261-1263 (1992)
	C24	Janeway et al., "Appendix III. Cytokines and their receptors," Immuno Biology 5, Garland Publishing (2001) New York, NY pp677-679
	C25	Kabilan et al., "Detection of intracellular expression and secretion of Interferon-γ at the single-cell level after activation of human T cells with tetanus toxoid in vitro," Eur. J. Immunol. 20:1085-1089 (1990)
1.	C26	Kwok et al., "Use of class II tetramers for identification of CD4+ T cells," J. Immunol. Methods 268(1):71-81 (2002)
	C27	Lalvani et al., "Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells," Lancet 357:2017-2021 (2001)
	C28	Lalvani et al., "Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant <i>Plasmodium falciparum</i> malaria vaccine," <i>J. Inf. Dis.</i> 180:1656-1664 (1999)
	C29	Lalvani et al., "Rapid effector function in CD8+ memory T cells," J. Exp. Med. 186:859-865 (1997)
	C30	Lang et al., "A functional and structural basis for TCR cross-reactivity in multiple sclerosis," Nat. Immunol. 3(10):940-943 (2002)
	C31	Mashishi and Gray, "The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes," Clin. Chem. Lab. Med. 40(9):903-910 (2002)
	C32	Mathioudakis et al., "Multiparameter cytokine-specific affinity matrix assay for the determination of frequencies and phenotype of antigen-reactive T cells," J. Immunol. Methods 260(1-2):37-42 (2002)
	C33	Medhat et al., "Increased interleukin-4 and interleukin-5 production in response to schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment," J. Infect. Dis. 178:512-519 (1998)

1	Examiner Signature /Unsu Jung/	Date Considered 03/29/2007
	EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866	
1	closure Statement	Applicant Stern et al.,		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date April 14, 2004	Group Art Unit 1632	

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
/UJ/	C34	Merville et al., "Detection of single cells secreting IFN-gamma, IL-6 and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4," Transplantation 55:639-646 (1993)			
	C35	Munk et al., "Increased numbers of interleukin-12-producing cells in human tuberculosis," Infect. Immun. 64:1078-1080 (1996)			
	C36	Novitsky et al., "Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific Elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design," J. Virol. 75:9210-9228 (2001)			
	C37	Olsson et al., "Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of Interferon-γ," J. Clin. Invest. 86:981-985 (1990)			
	C38	Özenci et al., "IL-12 ELISpot assays to detect and enumerate IL-12 secreting cells," Cytokine 12:1218-1224 (2000)			
	C39	Perelson, "Modeling viral and immune system dynamics," Nat. Rev. Immunol. 2(1):28-36 (2002)			
	C40	Prakken et al., "Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'," Nature Medicine 6(12):1406-1410 (2000)			
	C41	Qian and Weiss, "T cell antigen receptor signal transduction," Curr. Opin. Cell. Biol. 9(2):205-212 (1997)			
	C42	Reich et al., "Self peptides isolated from MHC glycoproteins of non-obese diabetic mice," J. Immunol. 152(5):2279-2288 (1994)			
	C43	Rietz and Chen, "New B7 Family Members with Positive and Negative Costimulatory Function," American J. of Transplantation 4:8-14 (2004)			
	C44	Robinson et al., "IMGT/HLA databasea sequence database for the human major histocompatibility complex," Tissue Antigens. 55(3):280-287 (2000)			
	C45	Robinson et al., "IMGT/HLA Databasea sequence database for the human major histocompatibility complex," Nucleic Acids Res. 29(1):210-213 (2001)			
	C46	Robinson et al., "IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex," Nucleic Acids Res. 31(1):311-314 (2003)			
	C47	Rodda, "Peptide libraries for T cell epitope screening and characterization," J. Immunol. Methods 267(1):71-77 (2002)			
	C48	Rötzschke et al., "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," Nature 348(6298):252-254 (1990)			
	C49	Rudolph and Wilson, "The specificity of TCR/pMHC interaction," Curr. Opin. Immunol. 14(1):52-65 (2002)			
	C50	Schneider et al., "A prime-boost immunization regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees," Vaccine 19:4595-4602 (2001)			
	C51	Schwartz, "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," Cell 71(7):1065-1068 (1992)			
	C52	Soen et al., "Detection and Characterization of Cellular Immune Responses Using Peptide-MHC Microarrays," PloS Biology 1(3):429-438 (2003)			
\bigvee	C53	Southwood et al., "Several common HLA-DR types share largely overlapping peptide binding repertoires," J. Immunol. 160(7): 3363-3373 (1998)			

Examiner Signature /Unsu Jung/	Date Considered 03/29/2007
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

Substitute Form.PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Stern et al.,		
		Filing Date April 14, 2004	Group Art Unit 1632	

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
/UJ/	C54	Stern and Wiley, "The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide," Cell 68(3):465-477 (1992)
	C55	Taguchi et al., "Detection of individual mouse splenic T cells producing IFN- and IL-5 using the enzyme-linked immunospot (ELISPOT) assay," J. Immunol. Methods 128:65-73 (1990)
	C56	Van Bleek and Nathenson, "Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule," Nature 348(6298):213-216 (1990)
	C57	Van Epps et al., "Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein," J. Virol. 73(7): 5301-5308 (1999)
:	C58	Wang et al., "Induction of CD4+ T-cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine," Proc. Natl. Acad. Sci. USA 98: 10817 (2001) pp10817-10822
	C59	Wucherpfennig "Structural basis of molecular mimicry," J. Autoimmun. 16(3): 293-302 (2001)
	C60	Xu and Screaton, "MHC/peptide tetramer-based studies of T cell function," J. Immunol. Methods 268(1):21-28 (2002)
V	C61	Zaru et al., "Cutting edge: TCR engagement and triggering in the absence of large-scale molecular segregation at the T cell-APC contact site," J. Immunol. 168(9):4287-4291 (2002)
	C62	

Examiner Signature /Unsu Jung/	Date Considered 03/29/2007							
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10823866	
	Filing Date		2004-04-14	
	First Named Inventor Lawr		wrence J. Stern	
	Art Unit		1632	
	Examiner Name			
	Attorney Docket Number	er	07917-212001	

					U.S.I	PATENTS		-	Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C)ate	of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1										
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	l	Add		
·	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
/UJ/	1	20030223994	A1	2003-1	2-04	Hoogenboom et al.					
If you wisl	h to ac	ı dd additional U.S. Publi	shed Ap	plication	citatio	ı n information p	lease click the Ade	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² i Code ⁴		Publication Date	Name of Patentee or Applicant of cited Document		vhere Rel	or Relevant	T5	
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T 5				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10823866		
Filing Date		2004-04-14		
First Named Inventor Law		ence J. Stern		
Art Unit		1632		
Examiner Name				
Attorney Docket Number		07917-212001		

					<u> </u>		
/UJ/	1	International Search Report and Written Opinion for International Application No. PCT/US04/11978, 6 pages (February 17, 2006)					
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner Signature /Unsu Jung/		Date Considered	03/27/2007				
*EXAMIN	IER: Ir	nitial if confor	reference considered, whether or not citati mance and not considered. Include copy	ion is in conformance with MPEP 609 of this form with next communication). Draw line through a to applicant.		
1 See Kind Standard S	Codes of T.3). 3	of USPT For Japa	O Patent Documents at <u>www.USPTO.GOV</u> or MPEF anese patent documents, the indication of the year of appropriate symbols as indicated on the document un n is attached.	9 901.04. ² Enter office that issued the docume	ent, by the two-letter code (W		